1998 Federal Register / Vol. 72, No. 10 / Wednesday, January 17, 2007 / Notices 

desist from the aforementioned alleged 

violations of the Act; (b) order PANYNJ 

to pay reparations for any violations of 

the Act plus interest, costs, attorney’s 

fees, and any other damages to be 

determined; (c) command PANYNJ to 

comply with all applicable provisions of 

the Agreement; and (d) any other relief 

as the Commission determines to be 

proper, fair, and just. 

This proceeding has been assigned to 

the Office of Administrative Law Judges. 

Hearing in this matter, if any is held, 

shall commence within the time 

limitations prescribed in 46 CFR 502.61, 

and only after consideration has been 

given by the parties and the presiding 

officer to the use of alternative forms of 

dispute resolution. The hearing shall 

include oral testimony and crossexamination in the discretion of the 

presiding officer only upon proper 

showing that there are genuine issues of 

material fact that cannot be resolved on 

the basis of sworn statements, affidavits, 

depositions, or other documents or that 

the nature of the matter in issue is such 

that an oral hearing and crossexamination are necessary for the 

development of an adequate record. 

Pursuant to the further terms of 46 CFR 

502.61, the initial decision of the 

presiding officer in this proceeding shall 

be issued by January 8, 2008, and the 

final decision of the Commission shall 

be issued by May 7, 2008. 

Bryant L. VanBrakle, 

Secretary. 

[FR Doc. E7–496 Filed 1–16–07; 8:45 am] 

BILLING CODE 6730–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the National Vaccine 

Advisory Committee 

AGENCY: Department of Health and 

Human Services, Office of the Secretary. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (DHHS) is hereby giving notice 

that the National Vaccine Advisory 

Committee (NVAC) will hold a meeting. 

The meeting is open to the public. 

DATES: The meeting will be held on 

February 5, 2007, from 9 a.m. to 5 p.m., 

and on February 6, 2007, from 9 a.m. to 

12 p.m. 

ADDRESSES: Department of Health and 

Human Services; Hubert H. Humphrey 

Building, Room 800; 200 Independence 

Avenue, SW., Washington, DC 20201. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Emma English, Program Analyst, 

National Vaccine Program Office, 

Department of Health and Human 

Services, Room 443–H Hubert H. 

Humphrey Building, 200 Independence 

Avenue, SW., Washington, DC 20201; 

(202) 690–5566, nvpo@hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 2101 of the Public Service 

Act (42 U.S.C. 300aa–1), the Secretary of 

Health and Human Services was 

mandated to establish the National 

Vaccine Program to achieve optimal 

prevention of human infectious diseases 

through immunization and to achieve 

optimal prevention against adverse 

reactions to vaccines. The National 

Vaccine Advisory Committee was 

established to provide advice and make 

recommendations to the Assistant 

Secretary for Health, as the Director of 

the National Vaccine Program, on 

matters related to the program’s 

responsibilities. 

Topics to be discussed at the meeting 

include the 2006–2007 influenza 

season, Departmental vaccine priorities, 

adolescent and adult immunization, 

immunization registry systems, and the 

Pandemic and All-Hazards 

Preparedness Act. Subcommittee 

meetings will be held on the morning of 

February 6, 2007. A tentative agenda is 

currently available on the NVAC Web 

site: http://www.hhs.gov/nvpo/nvac. 

Public attendance at the meeting is 

limited to space available. Individuals 

must provide a photo ID for entry into 

the Humphrey Building. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

designated contact person. Members of 

the public will have the opportunity to 

provide comments at the meeting. 

Public comment will be limited to five 

minutes per speaker. Any members of 

the public who wish to have printed 

material distributed to NVAC members 

should submit materials to the 

Executive Secretary, NVAC, through the 

contact person listed above prior to 

close of business January 31, 2007. Preregistration is required for both public 

attendance and comment. Any 

individual who wishes to attend the 

meeting and/or participate in the public 

comment session should e-mail 

nvpo@hhs.gov or call 202–690–5566. 

Dated: January 11, 2007. 

Bruce Gellin, 

Director, National Vaccine Program Office. 

[FR Doc. E7–553 Filed 1–16–07; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel: Childhood 

Agricultural Safety and Health 

Research, Request for Applications 

(RFA) OH–07–002 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces a meeting of the 

aforementioned Special Emphasis 

Panel. 

Time and Date: 8 a.m.–5 p.m., February 6, 

2007 (Closed). 

Place: Residence Inn Marriott, 1456 Duke 

Street, Alexandria, Virginia 22314. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the review, discussion, and 

evaluation of research grant applications in 

response to RFA OH–07–002, ‘‘Childhood 

Agricultural Safety and Health Research.’’

Contact Person for More Information: Steve 

Olenchock, Scientific Review Administrator, 

National Institute for Occupational Safety 

and Health, 1095 Willowdale Road, 

Morgantown, WV 26506, telephone (304) 

285–6271. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Elaine Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–506 Filed 1–16–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects 

Title: Uniform Project Description 

(UPD) Program Narrative for 

Discretionary Grant Application Form 

OMB No. 0970–0139. 

Description: The Administration for 

Children and Families (ACF) has more 

mstockstill on PROD1PC61 with NOTICES

Federal Register / Vol. 72, No. 10 / Wednesday, January 17, 2007 / Notices 1999 

than 40 discretionary grant programs. 

The proposed information collection 

form would be a uniform discretionary 

application form eligible for use by 

grant applications to submit project 

information in response to ACF program 

announcements. ACF would use this 

information, along with other OMBapproved information collections, to 

evaluate and rank applicants and 

protect the integrity of the grantee 

selection process. All ACF discretionary 

grant programs would be eligible but not 

required to use this application form. 

The application consists of general 

information and instructions; the 

Standard Form 424 series that requests 

basic information, budget information, 

budget information and assurances; the 

Project Description requesting the 

applicant to describe how these 

objectives will be achieved; along with 

assurances and certifications. Guidance 

for the content of information requested 

in the Project Description is found in 

OMB Circulars A–102 and A–110. 

Respondents: Applicants for ACF 

Discretionary Grant Programs. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average burden 

hours per 

response 

Total burden 

hours 

UPD ................................................................................................................. 11,960 1 40 478,400 

Estimated Total Annual Burden 

Hours: 478,400. 

In compliance with the requirements 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: January 11, 2007. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 07–127 Filed 1–16–07; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006D–0514] 

Draft Guidance for Industry: Minimally 

Manipulated, Unrelated, Allogeneic 

Placental/Umbilical Cord Blood 

Intended for Hematopoietic 

Reconstitution in Patients with 

Hematological Malignancies; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of a draft document entitled 

‘‘Guidance for Industry: Minimally 

Manipulated, Unrelated, Allogeneic 

Placental/Umbilical Cord Blood 

Intended for Hematopoietic 

Reconstitution in Patients with 

Hematological Malignancies’’ dated 

December 2006. The draft guidance 

document provides recommendations 

that would allow the manufacturer, 

generally a cord blood bank, to apply for 

licensure of minimally manipulated, 

unrelated, allogeneic placental/ 

umbilical cord blood, for specified 

indications. The document also contains 

information about the manufacture of 

minimally manipulated, unrelated, 

allogeneic placental/umbilical cord 

blood and how to comply with 

applicable regulatory requirements. 

DATES: Submit written or electronic 

comments on the draft guidance by 

April 17, 2007 to ensure their adequate 

consideration in preparation of the final 

guidance. General comments on agency 

guidance documents are welcome at any 

time. 

ADDRESSES: Submit written requests for 

single copies of the draft guidance to the 

Office of Communication, Training, and 

Manufacturers Assistance (HFM–40), 

Center for Biologics Evaluation and 

Research (CBER), Food and Drug 

Administration, 1401 Rockville Pike, 

suite 200N, Rockville, MD 20852–1448. 

Send one self-addressed adhesive label 

to assist the office in processing your 

requests. The draft guidance may also be 

obtained by mail by calling CBER at 1–

800–835–4709 or 301–827–1800. See 

the SUPPLEMENTARY INFORMATION section 

for electronic access to the draft 

guidance document. 

Submit written comments on the draft 

guidance to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.fda.gov/dockets/ecomments. 

FOR FURTHER INFORMATION CONTACT: 

Kathleen E. Swisher, Center for 

Biologics Evaluation and Research 

(HFM–17), Food and Drug 

Administration, 1401 Rockville Pike, 

suite 200N, Rockville, MD 20852–1448, 

301–827–6210. 

SUPPLEMENTARY INFORMATION: 

I. Background 

FDA is announcing the availability of 

a draft document entitled ‘‘Guidance for 

Industry: Minimally Manipulated, 

Unrelated, Allogeneic Placental/ 

Umbilical Cord Blood Intended for 

Hematopoietic Reconstitution in 

Patients with Hematological 

Malignancies’’ dated December 2006. 

The draft guidance document provides 

recommendations that would allow the 

manufacturer, generally a cord blood 

bank, to apply for licensure of 

minimally manipulated, unrelated, 

allogeneic placental/umbilical cord 

blood, for specified indications. The 

mstockstill on PROD1PC61 with NOTICES